A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Inclusion Criteria: * Subjects with a histopathological diagnosis of HCC * Subjects who have undergone a curative resection or ablation (radiofrequency ablation \[RFA\] or microwave ablation \[MVA\] only) * No previous systematic treatment and locoregional therapy for HCC prior to randomization * Absence of major macrovascular invasion * No extrahepatic spread * Full recovery from Curative resection or ablation within 4 weeks prior to randomization * High risk for HCC recurrence after resection or ablation * For patients who received post-operative transarterial chemoembolization: full recovery from the procedure within 4 weeks prior to randomization * Child-Pugh Class: Grade A * ECOG-PS score: 0 or 1 * Subjects with HCV- RNA (+) must receive antiviral therapy * Adequate organ function Exclusion Criteria: * Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and fibrolamellar HCC; other active malignant tumor except HCC within 5 years or simultaneously * Evidence of residual lesion, recurrence, and metastasis at randomization; * Moderate-to-severe ascites with clinical symptoms * History of hepatic encephalopathy * History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal haemorrhage * Active or history of autoimmune disease * Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity * Cardiac clinical symptom or cardiovascular disease that is not well controlled * Severe infection within 4 weeks prior to the start of study treatment * HIV infection * Known history of serious allergy to any monoclonal antibody or targeted anti-angiogenic drug * Subjects with inadequately controlled hypertension or history of hypertensive crisis or hypertensive encephalopathy * Thrombosis or thromboembolic event within 6 months prior to the start of study treatment * Known genetic or acquired hemorrhage or thrombotic tendency * Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment * Serious non-healing or dehiscing wound * Major Curative procedure within four weeks * Factors to affect oral administration * Previous or current presence of metastasis to central nervous system